α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia

Schizophrenia Research

Volumn 136, Issue 1-3, 2012, Pages 82-87

  Kucinski, A ^a   Syposs, C ^a   Wersinger, S ^b   Bencherif, M ^c   Stachowiak, M K ^a   Stachowiak, E K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c TARGACEPT INC   (United States)

Author keywords

FGF receptor 1; In vivo microdialysis; Midbrain dopamine neurons; Nicotinic acetylcholine receptors; Sensory gating

Indexed keywords

DOPAMINE; FIBROBLAST GROWTH FACTOR 1; NICOTINIC AGENT; TC 7020; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATECHOLAMINE NERVE CELL; CELL DENSITY; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; EXTRACELLULAR MATRIX; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; MOUSE; NERVE STIMULATION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; SCHIZOPHRENIA; SENSORY GATING; SIGNAL TRANSDUCTION; STARTLE REFLEX; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC MOUSE; VENTRAL TEGMENTUM;

3,4-DIHYDROXYPHENYLACETIC ACID; ACOUSTIC STIMULATION; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRODIALYSIS; NEURAL INHIBITION; NICOTINIC AGONISTS; QUINUCLIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SCHIZOPHRENIA; SENSORY GATING; STARTLE REACTION; THIOPHENES;

EID: 84857994610     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.01.005     Document Type: Article

References (59)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155(6):761-767.
2. Acker B.A., Jacobsen E.J., Rogers B.N., Wishka D.G., Reitz S.C., Piotrowski D.W., Myers J.K., Wolfe M.L., Groppi V.E., Thornburgh B.A., Tinholt P.M., Walters R.R., Olson B.A., Fitzgerald L., Staton B.A., Raub T.J., Krause M., Li K.S., Hoffmann W.E., Hajos M., Hurst R.S., Walker D.P. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg. Med. Chem. Lett 2008, 18(12):3611-3615.
3. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 1993, 150(12):1856-1861.
4. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am. J. Psychiatry 1999, 156(4):596-602.
5. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(6):2569-2574.
6. Campos F., Alfonso M., Duran R. In vivo modulation of alpha7 nicotinic receptors on striatal glutamate release induced by anatoxin-A. Neurochem. Int. 2010, 56(6-7):850-855.
7. Champtiaux N., Gotti C., Cordero-Erausquin M., David D.J., Przybylski C., Lena C., Clementi F., Moretti M., Rossi F.M., Le Novere N., McIntosh J.M., Gardier A.M., Changeux J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci. 2003, 23(21):7820-7829.
8. Cools R. Dopaminergic control of the striatum for high-level cognition. Curr. Opin. Neurobiol. 2011, 21(3):402-407.
9. Davis M., Gendelman P.M. Plasticity of the acoustic startle response in the acutely decerebrate rat. J. Comp. Physiol. Psychol. 1977, 91(3):549-563.
10. Finlay J.M., Zigmond M.J. The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem. Res. 1997, 22(11):1387-1394.
11. Freedman R., Adams C.E., Leonard S. The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia. J. Chem. Neuroanat. 2000, 20(3-4):299-306.
12. George T.P., Termine A., Sacco K.A., Allen T.M., Reutenauer E., Vessicchio J.C., Duncan E.J. A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr. Res. 2006, 87(1-3):307-315.
13. Geyer M.A., McIlwain K.L., Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry 2002, 7(10):1039-1053.
14. Goto Y., Otani S., Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 2007, 53(5):583-587.
15. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi I., Moretti M., Pedrazzi P., Pucci L., Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 2009, 78(7):703-711.
16. Grahn J.A., Parkinson J.A., Owen A.M. The role of the basal ganglia in learning and memory: neuropsychological studies. Behav. Brain Res. 2009, 199(1):53-60.
17. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10(8):1779-1782.
18. Hajos M., Hurst R.S., Hoffmann W.E., Krause M., Wall T.M., Higdon N.R., Groppi V.E. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 2005, 312(3):1213-1222.
19. Hauser T.A., Kucinski A., Jordan K.G., Gatto G.J., Wersinger S.R., Hesse R.A., Stachowiak E.K., Stachowiak M.K., Papke R.L., Lippiello P.M., Bencherif M. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem. Pharmacol. 2009, 78(7):803-812.
20. Hernandez L.F., Segovia G., Mora F. Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study. Neurochem. Res. 2003, 28(12):1819-1827.
21. Hong L.E., Wonodi I., Lewis J., Thaker G.K. Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology 2008, 33(9):2167-2174.
22. Jones I.W., Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J. Neurosci. 2004, 24(50):11244-11252.
23. Kaiser S., Wonnacott S. Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 2000, 58(2):312-318.
24. Kegeles L.S., Frankle W.G., Gil R., Narendran R., Slifstein M., Hwang D.R., Cangiano C., Haber S.N., Abi-Dargham A., Laruelle M. Schizophrenia is associated with increased synaptic dopamine in associative rather than limbic regions of the striatum: implications for mechanisms of action of antipsychotic drugs. J. Nucl. Med. 2006, 47:139.
25. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., Maher P.A., Hard R., Richards J., Stachowiak E.K., Stachowiak M.K. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J. Neurochem. 2006, 97(5):1243-1258.
26. Klejbor I., Kucinski A., Wersinger S.R., Corso T., Spodnik J.H., Dziewiatkowski J., Morys J., Hesse R.A., Rice K.C., Miletich R., Stachowiak E.K., Stachowiak M.K. Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis. Schizophr. Res. 2009, 113(2-3):308-321.
27. Kohnomi S., Suemaru K., Goda M., Choshi T., Hibino S., Kawasaki H., Araki H. Ameliorating effects of tropisetron on dopaminergic disruption of prepulse inhibition via the alpha(7) nicotinic acetylcholine receptor in Wistar rats. Brain Res. 2010, 1353:152-158.
28. Kreitzer A.C., Malenka R.C. Striatal plasticity and basal ganglia circuit function. Neuron 2008, 60(4):543-554.
29. Kucinski A.J., Stachowiak M.K., Wersinger S.R., Lippiello P.M., Bencherif M. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia. Curr. Pharm. Biotechnol. 2011, 12(3):437-448.
30. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(17):9235-9240.
31. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46(1):56-72.
32. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., Freedman R. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch. Gen. Psychiatry 2002, 59(12):1085-1096.
33. Leonard S., Mexal S., Freedman R. Smoking, genetics and schizophrenia: evidence for self medication. J. Dual. Diagn. 2007, 3(3-4):43-59.
34. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 2006, 63(10):1372-1376.
35. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 2008, 31(5):234-242.
36. Mansbach R.S., Geyer M.A., Braff D.L. Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology (Berl) 1988, 94(4):507-514.
37. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?. Mol. Pharmacol. 2010, 77(3):317-326.
38. Marrero M.B., Lucas R., Salet C., Hauser T.A., Mazurov A., Lippiello P.M., Bencherif M. An alpha7 nicotinic acetylcholine receptor-selective agonist reduces weight gain and metabolic changes in a mouse model of diabetes. J. Pharmacol. Exp. Ther. 2010, 332(1):173-180.
39. Martin L.F., Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int. Rev. Neurobiol. 2007, 78:225-246.
40. Martin L.F., Kem W.R., Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004, 174(1):54-64.
41. Martin L.F., Leonard S., Hall M.H., Tregellas J.R., Freedman R., Olincy A. Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144B(5):611-614.
42. Mizrahi R., Addington J., Rusjan P.M., Suridjan I., Ng A., Boileau I., Pruessner J.C., Remington G., Houle S., Wilson A.A. Increased stress-induced dopamine release in psychosis. Biol. Psychiatry 2011, (Electronic publication ahead of print).
43. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52(12):998-1007.
44. Powell S.B., Zhou X., Geyer M.A. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain. Res. 2009, 204(2):282-294.
45. Ralph R.J., Paulus M.P., Fumagalli F., Caron M.G., Geyer M.A. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 2001, 21(1):305-313.
46. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10(5):434-449.
47. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 2004, 65(6):1526-1535.
48. Segovia G., Del Arco A., Mora F. Endogenous glutamate increases extracellular concentrations of dopamine, GABA, and taurine through NMDA and AMPA/kainate receptors in striatum of the freely moving rat: a microdialysis study. J. Neurochem. 1997, 69(4):1476-1483.
49. Sesack S.R., Grace A.A. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010, 35(1):27-47.
50. Simpson E.H., Kellendonk C., Kandel E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65(5):585-596.
51. Suemaru K., Yasuda K., Umeda K., Araki H., Shibata K., Choshi T., Hibino S., Gomita Y. Nicotine blocks apomorphine-induced disruption of prepulse inhibition of the acoustic startle in rats: possible involvement of central nicotinic alpha7 receptors. Br. J. Pharmacol. 2004, 142(5):843-850.
52. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 1998, 24(2):285-301.
53. Swerdlow N.R., Taaid N., Oostwegel J.L., Randolph E., Geyer M.A. Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats. Behav. Pharmacol. 1998, 9(5-6):389-396.
54. Thomsen M.S., Hansen H.H., Timmerman D.B., Mikkelsen J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 2010, 16(3):323-343.
55. Tietje K.R., Anderson D.J., Bitner R.S., Blomme E.A., Brackemeyer P.J., Briggs C.A., Browman K.E., Bury D., Curzon P., Drescher K.U., Frost J.M., Fryer R.M., Fox G.B., Gronlien J.H., Hakerud M., Gubbins E.J., Halm S., Harris R., Helfrich R.J., Kohlhaas K.L., Law D., Malysz J., Marsh K.C., Martin R.L., Meyer M.D., Molesky A.L., Nikkel A.L., Otte S., Pan L., Puttfarcken P.S., Radek R.J., Robb H.M., Spies E., Thorin-Hagene K., Waring J.F., Ween H., Xu H., Gopalakrishnan M., Bunnelle W.H. Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties. CNS Neurosci. Ther. 2008, 14(1):65-82.
56. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr. Bull. 2010, 36(2):246-270.
57. Wallace T.L., Callahan P.M., Tehim A., Bertrand D., Tombaugh G., Wang S., Xie W., Rowe W.B., Ong V., Graham E., Terry A.V., Rodefer J.S., Herbert B., Murray M., Porter R., Santarelli L., Lowe D.A. RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2011, 336(1):242-253.
58. Wan F.J., Geyer M.A., Swerdlow N.R. Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology (Berl) 1995, 120(4):433-441.
59. Wong A.H., Van Tol H.H. Schizophrenia: from phenomenology to neurobiology. Neurosci. Biobehav. Rev. 2003, 27(3):269-306.